Novartis Reports Stronger Q2 Profits Amid Transition to New Medicines
In its second quarter of fiscal year 2026, Swiss pharmaceutical giant Novartis reported stronger-than-expected profits despite ongoing challenges from patent expirations. Core operating income reached $5.94 billion, surpassing analyst forecasts and showing resilience as newer drugs offset declining sales in older products.
Tickers: $NVS
Topics: drug sales patent expiration pharmaceuticals revenue growth